Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
QIMC Reports Record 30.0% Clean Natural Hydrogen at 413 Metres as Pressurized Free Gas Observations Trigger Repeated Hydrogen Alarms at Bennett Hill, Nova Scotia
Angkor Resources Reports Visual Copper Mineralization In 2026 Drill Core From Andong BOR License, Cambodia
